MiMedx To Present At Canaccord’s 10th Annual Musculoskeletal Conference

MARIETTA, Ga., March 16, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at Canaccord’s 10th Annual Musculoskeletal Conference in Las Vegas, Nevada. Parker H. “Pete” Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 24th at 10:00 a.m. PDT/1:00 p.m. EDT, at the MGM Grand Hotel. A webcast of this presentation will be available on the Company’s website, www.mimedx.com.

MiMedx will also be exhibiting the Company’s human amniotic membrane allograft tissue technologies at the 2015 Annual Meeting of the American Association of Orthopaedic Surgeons. Throughout the conference, MiMedx plans to hold various meetings with physicians, scientists and investors to discuss and demonstrate the benefits and potential of our PURION® Processed allografts. MiMedx Group will be located in Booth 855 at the Venetian/Sands EXPO, Las Vegas, Nevada.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 350,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-to-present-at-canaccords-10th-annual-musculoskeletal-conference-300051130.html

SOURCE MiMedx Group, Inc.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC